Affiliation:
1. From the Swiss Group for Clinical Cancer Research (SAKK), and the Department of Urology, University of Bern, Bern, Switzerland
Abstract
Purpose To determine if immediate hormonal therapy is advantageous compared with deferred treatment in newly diagnosed asymptomatic prostate cancer patients who, for any reason, were not candidates for curative local treatment. Patients and Methods Between February 1988 and February 1992, 197 patients with a median age of 76 years (range, 56 to 86 years) were randomly assigned to receive either immediate or deferred orchiectomy on symptomatic progression. The two groups did not differ significantly in clinical or laboratory parameters; 67% had T3-4 tumors and 20% had lymph node metastases. Patient accrual was stopped prematurely because of a similar competing trial. Therefore, observation time was prolonged to achieve the desired number of events and statistical power. Results Deferred orchiectomy was necessary in 58% of the patients. Median time to disease progression was 2.8 years less than for patients with immediate orchiectomy. However, overall pain-free time from random assignment to symptomatic progression after immediate or deferred orchiectomy, and performance status, were identical in both groups. Cancer-specific survival tended to be longer in the immediate group (P = .09) but there was no difference in overall survival between the two groups (P = .96). The median hemoglobin value decreased significantly after immediate orchiectomy (P < .001). Conclusion For elderly, asymptomatic patients not undergoing curative local treatment, we were unable to show any major advantage of immediate compared with deferred hormonal treatment regarding quality of life or overall survival in our limited number of patients. Disabling complications were prevented in the deferred-treatment arm by careful follow-up; 42% of these patients never required any tumor-specific treatment.
Publisher
American Society of Clinical Oncology (ASCO)
Reference24 articles.
1. Niehans P: Prostata-Krebs wie Paraprostata-Hypertrophie sind Folgen hormonaler Störun-gen, die wir je früher je besser beeinflussen können . Hans Huber, Bern, 1940
2. Huggins C, Hodges CV: Studies on prostatic cancer: Effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293,1941-297,
3. AN ANALYSIS OF WATCHFUL WAITING FOR CLINICALLY LOCALIZED PROSTATE CANCER
4. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer
5. The case for early endocrine treatment of advanced or metastatic prostate cancer
Cited by
81 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献